The Egyptian Pharmacovigilance Center (EPVC) Newsletter, June 2026 edition, presents critical safety information for healthcare professionals, including a regulatory update on insulin syringe safety to prevent medication errors, a pharmacovigilance analysis of labelled drug-drug interactions involving narrow therapeutic index drugs (valproic acid and methotrexate), and a detailed local case safety report documenting severe hypocalcaemia, secondary hyperparathyroidism, and hypophosphataemia following denosumab administration in a patient with end-stage renal disease.
This article provides a comprehensive medical analysis of these updates, exploring the clinical pharmacology, mechanisms of toxicity, risk factors, and practical recommendations for healthcare providers.
Section 1: Safety Update – Use of Insulin-Specific Syringes to Prevent Medication Errors During Insulin Administration
1.1 Background and Regulatory Context
The regulatory authority in Japan, the Pharmaceuticals and Medical Devices Agency (PMDA), published Medical Safety Information No. 73 in April 2026, highlighting a critical and repeatedly reported medication error: the use of general-purpose syringes (marked in mL) instead of insulin-specific syringes (marked in UNITS) for insulin administration.
Insulin is a high-alert medication for managing diabetes mellitus. It is administered via subcutaneous injection using insulin vials and syringes. Precise dosing in units (U) is essential to prevent hypoglycaemia, hyperglycaemia, and long-term complications. However, a critical medication error has been repeatedly reported: incorrect unit conversion when general-purpose syringes (marked in mL) are used instead of insulin-specific syringes (marked in UNITS). This results in doses far exceeding the intended dose, causing serious adverse events.
1.2 The Nature of the Error
The core problem lies in the difference between the two syringe types:
| Syringe Type | Calibration | Risk |
|---|---|---|
| Insulin-specific syringe | Marked in UNITS | Safe for insulin administration; no conversion needed |
| General-purpose syringe | Marked in mL | Requires conversion (1 unit = 0.01 mL for U-100 insulin); highly error-prone |
The error typically occurs when a healthcare professional or patient uses a general-purpose syringe (e.g., a 1 mL or 5 mL syringe marked in 0.01 mL or 0.1 mL increments) to draw up insulin. Without proper conversion, a dose of “4 units” may be misinterpreted as “4 mL” – a 100-fold overdose. In one documented case, a nurse who knew about the dedicated insulin syringe mistakenly thought that 4 units of insulin was 4 mL and administered 400 units of Humulin R subcutaneously.
1.3 Clinical Consequences of Insulin Overdose
| Consequence | Mechanism | Clinical Presentation |
|---|---|---|
| Severe hypoglycaemia | Excessive insulin drives glucose into cells, causing dangerously low blood glucose | Sweating, palpitations, confusion, seizures, loss of consciousness, coma, death |
| Hyperglycaemia (paradoxical) | If the error is detected late or if the patient does not seek care | Polyuria, polydipsia, diabetic ketoacidosis |
| Long-term complications | Repeated errors lead to poor glycaemic control | Microvascular and macrovascular complications |
1.4 Recommendations for Healthcare Professionals
Hospital Settings
| Recommendation | Action |
|---|---|
| Implement set dispensing system | Dispense insulin and insulin-specific syringes as a set |
| Place warning signs | Display visible warnings on insulin storage areas |
| Make syringe verification mandatory | Require verification of syringe type before each insulin administration |
| Report errors | Report medication errors to the pharmacovigilance system |
Pharmacy Practice
| Recommendation | Action |
|---|---|
| Always dispense insulin-specific syringes with insulin | Never dispense insulin without the appropriate syringe |
| Provide clear patient instructions | Counsel patients on the correct syringe to use |
| Document syringe dispensing | Maintain records of syringe dispensing |
Key Messages for Patients and Caregivers
| Message | Action |
|---|---|
| Always use insulin-specific syringes | Use syringes marked in UNITS, never mL |
| Verify before injection | Confirm the syringe is insulin-specific |
| Wrong syringe = wrong dose | Can cause severe hypoglycaemia or hyperglycaemia |
| Store together | Keep insulin and syringes together |
| Ask for help | Contact your pharmacist if unsure which syringe to use |
| Report errors | Report any medication errors to your healthcare provider |
Section 2: Enhancing Patient Safety Through Awareness of Labelled Drug-Drug Interactions – Focus on Narrow Therapeutic Index Drugs
2.1 Background and Objectives
Pharmacovigilance serves as the foundation of patient safety, leveraging systematic real-world data analysis to detect and mitigate adverse drug reactions (ADRs). Drug-drug interactions (DDIs) involving narrow therapeutic index (NTI) drugs present critical safety risks, particularly in polypharmacy.
The objectives of the EPVC analysis were to:
- Evaluate the clinical burden of labelled DDIs for valproic acid (VPA) and methotrexate (MTX) using individual case safety reports (ICSRs)
- Recommend appropriate risk minimisation awareness to reduce preventable drug-related problems
2.2 Methods
A retrospective signal detection study was conducted using the WHO global database of adverse event reports for medicines and vaccines (VigiBase). Two signals of disproportionate reporting (SDRs) were identified for reports with labelled DDIs:
| Drug | Number of Cases | Seriousness |
|---|---|---|
| Valproic acid (VPA) | 25 cases | 88% serious |
| Methotrexate (MTX) | 31 cases | 84% serious |
Descriptive statistics characterised the temporal distribution, seriousness, and clinical relevance, with a focus on the significant 2025 reporting spike.
2.3 Valproic Acid – Key Drug Interactions
Valproic acid is a broad-spectrum antiepileptic drug used for seizure disorders, bipolar disorder, and migraine prophylaxis. It has a narrow therapeutic index, and small changes in serum concentration can lead to significant clinical consequences.
2.3.1 Valproic Acid and Carbapenems (e.g., Meropenem)
The Interaction:
Co-administration of carbapenem antibiotics (including meropenem, imipenem, and ertapenem) with valproic acid or divalproex sodium results in a significant reduction in valproic acid concentrations.
Mechanism:
Although the precise mechanism is not fully understood, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thereby decreasing the serum concentrations of valproic acid.
Clinical Consequence:
Valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures.
Management:
- The concomitant use of valproic acid with carbapenem antibiotics is generally not recommended
- Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction
- Consider administration of antibacterial drugs other than carbapenems to treat infections in patients whose seizures are well controlled on valproic acid
- If administration of a carbapenem is necessary, consider supplemental anti-convulsant therapy
- Valproic acid levels typically begin to increase soon after discontinuation of the carbapenem
Reported Cases:
Seizures have been reported in several cases. The EPVC analysis demonstrated that VPA interactions caused pharmacokinetic shifts, resulting in a 20% incidence of breakthrough seizures (e.g., with meropenem) and 18% drug-related toxicity (e.g., with lamotrigine, phenytoin, carbamazepine).
2.3.2 Valproic Acid and Other Interactions
| Interacting Drug | Effect | Clinical Consequence |
|---|---|---|
| Lamotrigine | Increased lamotrigine levels (VPA inhibits lamotrigine metabolism) | Increased risk of lamotrigine toxicity (rash, Stevens-Johnson syndrome, ataxia) |
| Phenytoin | VPA displaces phenytoin from protein binding; variable effects on phenytoin metabolism | Increased free phenytoin levels; toxicity risk |
| Carbamazepine | Carbamazepine induces VPA metabolism; VPA may increase carbamazepine epoxide levels | Reduced VPA efficacy; increased carbamazepine toxicity |
2.4 Methotrexate – Key Drug Interactions
Methotrexate is an antimetabolite and antifolate agent used in oncology (high-dose) and autoimmune diseases (low-dose). It has a narrow therapeutic index, and toxicity can be severe.
2.4.1 Methotrexate and NSAIDs/Salicylates
The Interaction:
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can cause unexpectedly severe and fatal gastrointestinal toxicity when administered concomitantly with methotrexate, primarily at high-dose.
Mechanism:
NSAIDs and salicylates reduce the tubular secretion of methotrexate in an animal model and may enhance its toxicity. They may also displace methotrexate from plasma protein binding sites.
Clinical Consequence:
Increased methotrexate concentrations lead to enhanced toxicity, including myelosuppression, hepatotoxicity, nephrotoxicity, and gastrointestinal toxicity.
Management:
- Caution should be used when NSAIDs and salicylates are administered concomitately with lower doses of methotrexate
- Concomitant administration with high-dose methotrexate should generally be avoided
- Monitor for signs of methotrexate toxicity (mucositis, myelosuppression, renal impairment)
2.4.2 Methotrexate and Proton Pump Inhibitors (PPIs)
The Interaction:
Proton pump inhibitors may decrease the oral bioavailability of methotrexate and may interfere with its renal elimination.
Mechanism:
PPIs may affect the pH-dependent solubility of methotrexate, reducing its absorption. They may also compete for renal tubular secretion.
Clinical Consequence:
Reduced methotrexate efficacy (due to decreased absorption) or increased toxicity (due to decreased elimination).
Management:
- Consider alternative acid suppression therapies (e.g., H2-receptor antagonists) in patients on methotrexate
- Monitor methotrexate levels and clinical response
2.4.3 Methotrexate – Other Significant Interactions
2.5 Results from the EPVC Analysis
The EPVC analysis demonstrated:
| Parameter | Valproic Acid (VPA) | Methotrexate (MTX) |
|---|---|---|
| Total cases | 25 | 31 |
| Serious ADRs | 38.4% | 54.5% |
| Key outcomes | Breakthrough seizures (20%); drug-related toxicity (18%) | Pancytopenia (25.8%); renal impairment (16%); contraindicated co-administration (19.3%) |
| Primary interactions | Meropenem → reduced VPA levels; lamotrigine/phenytoin/carbamazepine → toxicity | NSAIDs/salicylates → increased toxicity; PPIs → reduced efficacy/increased toxicity |
2.6 Recommendations
The EPVC recommends:
- Raise awareness among stakeholders, healthcare providers, and patients of critical labelled DDIs, particularly those involving NTI products
- Integrate an artificial intelligence (AI) tool to support proactive risk-minimisation strategies
- Optimise therapeutic outcomes and reduce drug-related problems
- Strengthen medication safety in routine clinical practice
Section 3: Local Case Safety Report – Hypocalcaemia, Hyperparathyroidism, and Hypophosphataemia Following Denosumab Administration
3.1 Case Summary
The Cairo Regional Pharmacovigilance Center received an Individual Case Safety Report (ICSR) describing a 51-year-old female patient with end-stage renal disease (ESRD) on maintenance haemodialysis and a history of hypertension.
| Parameter | Details |
|---|---|
| Age/Sex | 51-year-old female |
| Medical history | ESRD on maintenance haemodialysis; hypertension |
| Treatment | Denosumab 60 mg subcutaneous injection (single dose) on 1 December 2025 |
| Indication | Primary osteoporosis |
| Baseline labs (November 2025) | Serum calcium: 10.99 mg/dL; Serum phosphorus: 4.9 mg/dL |
Post-Denosumab Biochemical Changes:
| Parameter | Baseline (Nov 2025) | 22 Dec 2025 | January 2026 |
|---|---|---|---|
| Total serum calcium | 10.99 mg/dL | 8.33 mg/dL | 8.22 mg/dL |
| Serum phosphorus | 4.9 mg/dL | 1.6 mg/dL | 2.2 mg/dL (partial recovery) |
| Parathyroid hormone (PTH) | 71.3 pg/mL (June 2025) | — | 571 pg/mL |
Clinical Presentation:
- Marked and persistent decline in mineral parameters
- Significant biochemical disturbances
- Dechallenge assessment considered not applicable (denosumab is a long-acting monoclonal antibody with activity persisting up to 6 months)
- Management relied on calcium and vitamin D supplementation
3.2 Background: Denosumab
Denosumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (Chinese hamster ovary cells) by recombinant DNA technology. It is a long-acting monoclonal antibody that remains active in the system for up to 6 months.
Mechanism of Action:
Denosumab binds with high affinity and specificity to Receptor Activator of Nuclear Factor κB Ligand (RANKL), preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption in cortical and trabecular bone.
3.3 Pathophysiology of Denosumab-Induced Mineral Metabolism Disturbances
The administration of denosumab is consistently associated with clinically relevant disturbances in mineral metabolism:
Step 1: Inhibition of Osteoclast-Mediated Bone Resorption
- Denosumab potently inhibits RANKL, reducing osteoclast activity
- This significantly reduces the release of calcium from bone into the systemic circulation
Step 2: Hypocalcaemia
- Reduced bone resorption → decreased serum calcium
- Hypocalcaemia is listed in the denosumab SmPC under metabolism and nutrition disorders
Step 3: Compensatory Secondary Hyperparathyroidism
- Reduced serum calcium triggers a compensatory increase in parathyroid hormone (PTH) secretion
- PTH levels rise significantly (as seen in the case: 71.3 → 571 pg/mL)
Step 4: Hypophosphataemia
- Elevated PTH increases renal phosphate excretion (phosphaturia)
- This exacerbates phosphate wasting, leading to hypophosphataemia
- Denosumab-induced secondary hyperparathyroidism results in phosphaturia, which subsequently impairs renal phosphate reabsorption
3.4 Risk Factors for Denosumab-Associated Hypocalcaemia
| Risk Factor | Explanation |
|---|---|
| Chronic kidney disease (CKD) | Patients with severe renal impairment (creatinine clearance <30 mL/min) or receiving dialysis are at greater risk |
| ESRD on haemodialysis | Dialysis patients obtain most of their calcium through bone due to poor intestinal absorption; denosumab’s potent anti-resorptive effect carries a high risk of hypocalcaemia |
| Vitamin D deficiency | Increases risk of hypocalcaemia; should be corrected before therapy |
| Low baseline calcium | Pre-existing hypocalcaemia is a contraindication |
| Secondary hyperparathyroidism | Common in CKD; denosumab can exacerbate hypocalcaemia |
| Concomitant calcimimetic drugs | May worsen hypocalcaemia risk in patients with advanced CKD |
3.5 Labelled Information
According to the Summary of Product Characteristics (SmPC) of denosumab:
- Hypocalcaemia is listed under metabolism and nutrition disorders as an adverse reaction
- Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy
- In the post-marketing setting, severe symptomatic hypocalcaemia (resulting in hospitalisation, life-threatening events, and fatal cases) has been reported
- While most cases occurred in the first few weeks of initiating therapy, it has also occurred later
- Patients with severe renal impairment (creatinine clearance <30 mL/min) or receiving dialysis are at greater risk of developing hypocalcaemia
- The risks of developing hypocalcaemia and accompanying PTH elevations increase with increasing degree of renal impairment
- Severe and fatal cases have been reported in these populations
3.6 Literature Evidence
3.7 Clinical Implications and Recommendations
3.7.1 Pre-Treatment Assessment and Optimisation
| Action | Details |
|---|---|
| Correct hypocalcaemia before initiation | Contraindication if present |
| Assess and optimise vitamin D status | Deficiency increases the risk of hypocalcaemia |
| Evaluate baseline laboratory parameters | Serum calcium, phosphate, magnesium, renal function, PTH (especially in CKD patients) |
| Identify high-risk patients | CKD, low baseline calcium, vitamin D deficiency |
3.7.2 Ensure Adequate Supplementation
| Action | Details |
|---|---|
| Provide routine calcium and vitamin D supplementation | To all patients |
| Maintain supplementation throughout the treatment period | Not only at initiation |
3.7.3 Laboratory Monitoring During Treatment
| Parameter | Frequency |
|---|---|
| Serum calcium | Before each dose; within 14 days post-injection (when levels typically decline); more frequently in high-risk patients |
| Phosphate and other electrolytes | Periodically, especially in high-risk patients |
| Vitamin D | Intermittently to ensure adequacy |
| CKD or high-risk patients | Weekly for the first month, then monthly |
3.7.4 Special Precautions in High-Risk Populations
| Recommendation | Action |
|---|---|
| Advanced CKD | Use cautiously; involve specialists |
| Concomitant calcimimetic drugs | May worsen hypocalcaemia risk |
| CKD-MBD assessment | Assess before treatment in CKD patients |
| Supervision | Treatment should be supervised by a healthcare provider with expertise in CKD-MBD |
| Pregnancy | May cause fetal harm; advise effective contraception during therapy and for at least 5 months after the last dose |
| Paediatric patients | Safety and effectiveness not established |
| Closer monitoring | Implement frequent calcium testing in high-risk populations |
3.7.5 Patient Education and Safety Measures
| Message | Action |
|---|---|
| Adherence to supplementation | Maintain calcium and vitamin D supplementation |
| Recognise symptoms of hypocalcaemia | Muscle spasms, paresthesia, seizures |
| Seek immediate medical evaluation | If symptoms occur |
3.7.6 Multidisciplinary Care Approach
Evidence suggests that integrated or multidisciplinary care pathways (including endocrinology/nephrology input) can reduce the incidence of severe hypocalcaemia in high-risk populations.
Section 4: EPVC Tips – Be Aware of Drug-Lab Test Interactions
The EPVC newsletter highlights an often-overlooked patient safety issue: drug-laboratory test interactions.
4.1 Key Principles
| Principle | Action |
|---|---|
| Inform the laboratory and healthcare provider | About all medications being taken, including prescription drugs, OTC medicines, herbal products, and supplements |
| Review unexpected laboratory results | In the context of the patient’s medication history |
| Consider drug-laboratory test interactions | Before making clinical decisions based on abnormal test results |
4.2 Examples of Drug-Lab Test Interactions
| Drug/Substance | Affected Tests | Effect |
|---|---|---|
| High-dose Vitamin C (Ascorbic Acid) | Glucose and urine tests | Interference leading to false results |
| Biotin supplements | Thyroid function tests; cardiac biomarker assays | Can affect thyroid function tests and certain cardiac biomarker assays |
| Some antibiotics | Liver, kidney, or coagulation tests | May influence test results |
4.3 Clinical Implications
Drug-lab test interactions can lead to:
- False-positive results → unnecessary investigations and anxiety
- False-negative results → missed diagnoses and delayed treatment
- Misleading findings → incorrect clinical decisions
Healthcare professionals should:
- Maintain a high index of suspicion for drug-lab test interactions
- Review medication lists when unexpected laboratory results are obtained
- Consider alternative explanations before acting on abnormal results
- Educate patients about the importance of disclosing all medications and supplements
Section 5: Clinical Takeaways and Conclusions
Key Messages from the June 2026 Issue
| Topic | Key Takeaway |
|---|---|
| Insulin Syringe Safety | Insulin-specific syringes (marked in UNITS) must be used for insulin administration. General-purpose syringes (marked in mL) should never be used due to the risk of fatal dosing errors. |
| Valproic Acid Interactions | Carbapenems (especially meropenem) reduce valproic acid levels, increasing the risk of breakthrough seizures. Concomitant use should generally be avoided. |
| Methotrexate Interactions | NSAIDs, salicylates, and PPIs can increase methotrexate toxicity. Careful monitoring and dose adjustment are essential. |
| Denosumab in CKD | Denosumab can cause severe hypocalcaemia, secondary hyperparathyroidism, and hypophosphataemia in patients with CKD/ESRD. Pre-treatment assessment, supplementation, and close monitoring are critical. |
| Drug-Lab Test Interactions | Many drugs can interfere with laboratory tests, leading to false results and incorrect clinical decisions. |
